OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults
Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 5, pp. 335-346
Open Access | Times Cited: 27
Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 5, pp. 335-346
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
Bin Tan, Xiaoming Zhang, Ahmadullah Ansari, et al.
Science (2024) Vol. 383, Iss. 6690, pp. 1434-1440
Open Access | Times Cited: 47
Bin Tan, Xiaoming Zhang, Ahmadullah Ansari, et al.
Science (2024) Vol. 383, Iss. 6690, pp. 1434-1440
Open Access | Times Cited: 47
Ensitrelvir Fumaric Acid: First Approval
Yahiya Y. Syed
Drugs (2024) Vol. 84, Iss. 6, pp. 721-728
Closed Access | Times Cited: 10
Yahiya Y. Syed
Drugs (2024) Vol. 84, Iss. 6, pp. 721-728
Closed Access | Times Cited: 10
Proof-of-concept studies with a computationally designed M pro inhibitor as a synergistic combination regimen alternative to Paxlovid
Christina Papini, Irfan Ullah, Amalendu P. Ranjan, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 17
Open Access | Times Cited: 8
Christina Papini, Irfan Ullah, Amalendu P. Ranjan, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 17
Open Access | Times Cited: 8
Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report
Yuki Miyata, Ryo Yamaguchi, Takehito Yamamoto, et al.
Journal of Pharmaceutical Health Care and Sciences (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Yuki Miyata, Ryo Yamaguchi, Takehito Yamamoto, et al.
Journal of Pharmaceutical Health Care and Sciences (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 10, pp. 785-797
Open Access | Times Cited: 11
Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 10, pp. 785-797
Open Access | Times Cited: 11
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors
Kaustav Khatua, Yugendar R. Alugubelli, Kai S. Yang, et al.
Antiviral Research (2024) Vol. 225, pp. 105874-105874
Closed Access | Times Cited: 4
Kaustav Khatua, Yugendar R. Alugubelli, Kai S. Yang, et al.
Antiviral Research (2024) Vol. 225, pp. 105874-105874
Closed Access | Times Cited: 4
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
Yongzhi Lu, Qi Yang, Ting Ran, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Yongzhi Lu, Qi Yang, Ting Ran, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Drug interaction evaluation of the novel phosphodiesterase type 5 inhibitor tunodafil (youkenafil): effects of tunodafil on omeprazole pharmacokinetics based on CYP2C19 gene polymorphism, and effects of ritonavir on tunodafil pharmacokinetics
Keli Wang, Juefang Ding, Minlu Cheng, et al.
European Journal of Pharmaceutical Sciences (2025) Vol. 206, pp. 107010-107010
Open Access
Keli Wang, Juefang Ding, Minlu Cheng, et al.
European Journal of Pharmaceutical Sciences (2025) Vol. 206, pp. 107010-107010
Open Access
Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (Mpro) with Noncovalent Preclinical Candidate, Mpro61
Jessica R. Kenneson, Christina Papini, Su Tang, et al.
ACS Bio & Med Chem Au (2025)
Open Access
Jessica R. Kenneson, Christina Papini, Su Tang, et al.
ACS Bio & Med Chem Au (2025)
Open Access
Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, et al.
Therapeutic Advances in Infectious Disease (2025) Vol. 12
Open Access
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, et al.
Therapeutic Advances in Infectious Disease (2025) Vol. 12
Open Access
Discovery and Clinical Development of Ensitrelvir: An Oral SARS‐CoV‐2 3CL Protease Inhibitor for the Treatment of COVID‐19
(2025), pp. 365-388
Closed Access
(2025), pp. 365-388
Closed Access
Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model
Michihito Sasaki, Tatsuki Sugi, Shun Iida, et al.
EBioMedicine (2023) Vol. 99, pp. 104950-104950
Open Access | Times Cited: 10
Michihito Sasaki, Tatsuki Sugi, Shun Iida, et al.
EBioMedicine (2023) Vol. 99, pp. 104950-104950
Open Access | Times Cited: 10
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 8
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 8
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
Yongzhi Lu, Qi Yang, Ting Ran, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Yongzhi Lu, Qi Yang, Ting Ran, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
COVID-19 pneumonia in lung transplant recipients: understanding risk factors and treatment outcomes in Japan
Toshikazu Watanabe, Takashi Hirama, Miki Akiba, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Toshikazu Watanabe, Takashi Hirama, Miki Akiba, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Minimal involvement of P-gp and BCRP in oral absorption of ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor, in a non-clinical investigation
Ryosuke Watari, Naomi Tamura, Shinpei Yoshida, et al.
Journal of Pharmaceutical Sciences (2024) Vol. 113, Iss. 9, pp. 2871-2878
Closed Access | Times Cited: 2
Ryosuke Watari, Naomi Tamura, Shinpei Yoshida, et al.
Journal of Pharmaceutical Sciences (2024) Vol. 113, Iss. 9, pp. 2871-2878
Closed Access | Times Cited: 2
Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor
Ryosuke Watari, Hiromi Sawada, Hiroshi Hashimoto, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 3, pp. 798-805
Closed Access | Times Cited: 6
Ryosuke Watari, Hiromi Sawada, Hiroshi Hashimoto, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 3, pp. 798-805
Closed Access | Times Cited: 6
Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 Mpro Inhibitors
Leon Jacobs, Aletta van der Westhuyzen, Nicole Pribut, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 10, pp. 1434-1440
Open Access | Times Cited: 5
Leon Jacobs, Aletta van der Westhuyzen, Nicole Pribut, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 10, pp. 1434-1440
Open Access | Times Cited: 5
Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA<sup>®</sup> Tablets 125 mg)
Yuko Tsuge, Yasuko Ariwa, K. Shibata
Folia Pharmacologica Japonica (2024) Vol. 159, Iss. 4, pp. 264-281
Closed Access | Times Cited: 1
Yuko Tsuge, Yasuko Ariwa, K. Shibata
Folia Pharmacologica Japonica (2024) Vol. 159, Iss. 4, pp. 264-281
Closed Access | Times Cited: 1
Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series
Hanako Naganawa, Y. Katada, Shunsaku Nakagawa, et al.
Journal of Pharmaceutical Health Care and Sciences (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Hanako Naganawa, Y. Katada, Shunsaku Nakagawa, et al.
Journal of Pharmaceutical Health Care and Sciences (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Design of SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
Bin Tan, Xiaoming Zhang, Ahmadullah Ansari, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Bin Tan, Xiaoming Zhang, Ahmadullah Ansari, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Discovery of macrocyclic covalent inhibitors for severe acute respiratory syndrome coronavirus 2 3CL protease
Xiubo Tang, Kai Hou, Xiao‐Wu Chen, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117846-117846
Closed Access
Xiubo Tang, Kai Hou, Xiao‐Wu Chen, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117846-117846
Closed Access
The problem of SARS-CoV-2 virus resistance to direct-acting antivirals
Е. Л. Гасич, Е. Н. Кроткова, A. D. Kasko, et al.
Biological Products Prevention Diagnosis Treatment (2024)
Open Access
Е. Л. Гасич, Е. Н. Кроткова, A. D. Kasko, et al.
Biological Products Prevention Diagnosis Treatment (2024)
Open Access
Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors
Bin Tan, Xueying Liang, Ahmadullah Ansari, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 20399-20420
Closed Access
Bin Tan, Xueying Liang, Ahmadullah Ansari, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 20399-20420
Closed Access
Population Pharmacokinetics of Ensitrelvir in Healthy Participants and Participants with SARS-CoV-2 Infection in the SCORPIO-SR Study
Tôru Ishibashi, Ryosuke Shimizu, Ryuji Kubota
Clinical Pharmacokinetics (2024)
Open Access
Tôru Ishibashi, Ryosuke Shimizu, Ryuji Kubota
Clinical Pharmacokinetics (2024)
Open Access
